Abstract
Background
Respiratory parameters are important predictors of prognosis in the COPD population. Global Initiative for Obstructive Lung Disease (GOLD) 2017 Update resulted in a vertical shift of patients across COPD categories, with category B being the most populous and clinically heterogeneous. The aim of our study was to investigate whether respiratory parameters might be associated with increased all-cause mortality within GOLD category B patients.
Methods
The data were extracted from the Czech Multicentre Research Database, a prospective, noninterventional multicenter study of COPD patients. Kaplan–Meier survival analyses were performed at different levels of respiratory parameters (partial pressure of oxygen in arterial blood [PaO2], partial pressure of arterial carbon dioxide [PaCO2] and greatest decrease of basal peripheral capillary oxygen saturation during 6-minute walking test [6-MWT]). Univariate analyses using the Cox proportional hazard model and multivariate analyses were used to identify risk factors for mortality in hypoxemic and hypercapnic individuals with COPD.
Results
All-cause mortality in the cohort at 3 years of prospective follow-up reached 18.4%. Chronic hypoxemia (PaO2 <7.3 kPa), hypercapnia (PaCO2 >7.0 kPa) and oxygen desaturation during the 6-MWT were predictors of long-term mortality in COPD patients with forced expiratory volume in 1 second ≤60% for the overall cohort and for GOLD B category patients. Univariate analyses confirmed the association among decreased oxemia (<7.3 kPa), increased capnemia (>7.0 kPa), oxygen desaturation during 6-MWT and mortality in the studied groups of COPD subjects. Multivariate analysis identified PaO2 <7.3 kPa as a strong independent risk factor for mortality.
Conclusion
Survival analyses showed significantly increased all-cause mortality in hypoxemic and hypercapnic GOLD B subjects. More important, PaO2 <7.3 kPa was the strongest risk factor, especially in category B patients. In contrast, the majority of the tested respiratory parameters did not show a difference in mortality in the GOLD category D cohort.
Supplementary materials
Acknowledgments
We thank the physicians of participating centers of the Czech multicenter research database of severe COPD, namely, Tomas Dvorak – Pulmonary Department, Hospital Mlada Boleslav, Petr Safranek – Pulmonary Department, University Hospital, Plzen, Ondrej Sobotik – Pulmonary Department, University Hospital Motol, Prague, Maria Majerciakova – Pulmonary Department, Hospital of St Svorad, Nitra, Slovakia, Jaroslav Lnenicka – Pulmonary Department, Masaryk Hospital, Usti nad Labem, Pavlina Musilova – Pulmonary Department, Jihlava Hospital, Barbora Novotna – Pulmonary Department, Bulovka Hospital, Prague, Zuzana Liptakova – Pulmonary Department, Ceske Budejovice Hospital, Eva Kocova, Michal Kopecky, Sarka Pracharova, Libor Nevoranek and Lukas Varhanik – University Hospital Hradec Kralove, Katerina Neumannova – Palacky University, Olomouc and Milada Sipkova – Pulmonary Department, Liberec Hospital. Special thanks to Ondrej Zindr – Karlovy Vary for English corrections. This research was funded by Ministry of Health of the Czech Republic (15/14/NAP, 5/15/NAP, and UHHK, 00179906), moreover by consortium of several pharmaceutical companies (Angelini CZ, AstraZeneca CZ, Boehringer Ingelheim CZ, Cipla CZ, CSL Behring CZ, GSK CZ, Novartis CZ and Sandoz CZ).
Disclosure
M Plutinsky has received payments on COPD lectures from Boehringer Ingelheim. P Popelkova has received consulting/lectures payment from AstraZeneca, Boehringer Ingelheim and Novartis regarding the COPD field within past 36 months. J Zatloukal has received payment related to COPD clinical trials from AstraZeneca, GSK and Novartis within past 36 months, and received consulting/lectures payment from AstraZeneca, Novartis, Angelini and Berlin-Chemie regarding the COPD field within past 36 months. E Volakova has received COPD research funding from GSK within past 36 months, and received consulting/lectures payment from Boehringer Ingelheim and Berlin-Chemie regarding the COPD field within past 36 months. L Heribanová has received COPD research funding from AstraZeneca within past 36 months. V Koblizek has received COPD research funding from Boehringer Ingelheim, and Novartis within past 36 months, and received consulting/lectures payment from Angelini, AstraZeneca, Berlin-Chemie, Boehringer Ingelheim, GSK, Mundipharma, Novartis and Sandoz regarding the COPD field within past 36 months. K Brat, K Hejduk, M Svoboda and M Fecaninova have not received any payments within past 36 months. The authors report no other conflicts of interest in this work.